Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Correlation between interaction strengths drives stability in large ecological networks.
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9. Cancer Res. 2010 Nov 01; 70(21):8907-16.
View in:
PubMed
subject areas
Adaptor Proteins, Signal Transducing
Animals
Aurora Kinases
Blotting, Western
Cell Adhesion
Cell Cycle
Cell Movement
Cell Proliferation
Dasatinib
Embryo, Mammalian
Female
Fibroblasts
Flow Cytometry
Fluorescent Antibody Technique
Lung Neoplasms
Mammary Glands, Animal
Mammary Neoplasms, Experimental
Mammary Tumor Virus, Mouse
Mice
Mice, SCID
NIH 3T3 Cells
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-akt
Pyrimidines
src-Family Kinases
Thiazoles
Xenograft Model Antitumor Assays
authors with profiles
Evgeny Izumchenko